2^nd International Conference on Metabolic Syndrome August 10-11, 2017 London,UK

Biography:

Brandon Davis earned his Ph.D. in Counseling Psychology from Texas A&M University in 2004. He began performing bariatric surgery pre-operative evaluations in 2006 and has now done over 1,300 such assessments. In 2011, he expanded his services to provide therapy to people struggling with obesity. In 2013, he earned a certification in bariatric counseling from the American Association of Bariatric Counselors. He has published two studies in the field of bariatrics relating to Metabolic Factor, which is a method of assessing a biological predisposition for obesity.

Abstract:

A new metric called Metabolic Factor (Resting Metabolic Rate/Weight) has previously been established that can differentiate between people who are obese, overweight and of normal weight. Previous studies were re-analyzed and found that people who lost weight did not experience a change in their Metabolic Factor. The current study measured the Metabolic Factor of 18 individuals before and after bariatric surgery. As expected, individuals lost nearly 100 pounds and therefore lowered their Resting Metabolic Rate from 2,614.3 to 1,954.4 kcal (p < 0.05). However, the pre-operative Metabolic Factor of 8.1 (1.1) calories/pound did not change significantly as it slightly increased to 8.6 (0.88) after surgery (p = 0.19). Weight loss was not statistically significantly correlated with change in Metabolic Factor (r = 0.22). The follow up Metabolic Factor negatively correlated with post-operative BMI, r = -0.48 (p < 0.05), indicating the higher the Metabolic Factor, the lower the post-operative BMI. This study seems to establish the possibility that Metabolic Factor is not simply a function of one’s current weight, but instead might be a stable characteristic unique to each individual.

Biography:

Hanan A Alfawaz is associate professor at King Saud University, Saudi Arabia. She has published more than 30 papers in ISI journals with high impact factor. She has been a speaker in national and international conferences. She is a member in Prince Mutaib Chair in Osteoporosis. She is also a supervisor for Master and Ph.D. students and member in many committees.

Abstract:

Few studies have reported the relationship between diet and Metabolic Syndrome (MS). Our aim is to identify the predictors of MS among obese, diabetic and cardiac Saudi patients, and to find out the relationship between MS and dietary pattern. A cross-sectional study, 448 obese, diabetic and Ischemic Heart Disease (IHD) patients were participated. Questionnaire and multiple 24h dietary recall for three consecutive days were designed for this study. Biochemical indices of glucose, and lipids,anthropometric and BP were  measured. The prevalence of MS among subjects using the criteria of modified National Cholesterol Education Program and Adult Treatment Panel III (mNCEP-ATP III) and International Diabetes Federation (IDF) were found to be 80.1% and 75.4% respectively. MS was significantly (p≤0.05) higher among male. According to the MnCEP-ATP III definition low HDL-C was the most common indicator of MS. Abdominal obesity was significantly (p≤0.05) higher in female. According to the IDF definition abdominal obesity was the most common indicator of the MS. There were a high consumption of cholesterol and saturated fatty acids and low consumption of polyunsaturated fatty acids among these patients. Significant relationships (p ≤0.05) were found between consumption of red meat, fast food and animal fats and presence of MS predictors. Significant relationships (p ≤0.05) were found between consumption of grain and grain products and legumes and higher triacylglycerol (TAG) level. The study includes some other relationships between MS and the dietary pattern. The prevalence of MS among these patients was extremely high, which supposed to be controlled by both medications and diet. Consumption of certain diet elements has strong relation to development of MS.

Biography:

Jeffrey L. Kibler completed his Ph.D. from the University of Miami and postdoctoral studies from the University of Mississippi Medical Centre. He is the director of the Biofeedback and Health Psychology Centre at Nova Southeastern University. He has more than 30 scientificp ublications and routinely serves as a grant reviewer for U.S. federal and Italian Ministry of  Health proposals for research grant funding.

Abstract:

Post-traumatic stress disorder (PTSD), is a disorder of extreme stress/anxiety responses to a psychologically traumatic experience, has been associated with significantly greater incidence of heart disease and prevalence of metabolic syndrome. This higher risk for cardiovascular disease (CVD) in PTSD appears to be, in part, due to difficulties maintaining healthy lifestyles (e.g., weight management through healthy diet and regular physical activity, adequate sleep) and coping with daily stressors. The need for developing effective CVD prevention programs for adults with PTSD is increasingly evident. Therefore additional research is needed to examine programs that may reduce health risk behaviours and prevent early onset of CVD. The present project is a pilot study to examine whether a treatment program focused on healthy lifestyle behaviours (physical activity, good nutrition, sleep hygiene) and stress management will be associated with reductions in the levels of CVD risk variables (e.g., body weight, lipids, blood pressure) for adults with chronic PTSD and least one of the targeted health risks.This presentation illustrates the development of the intervention program, and the  design of the study measurement. Results of preliminary cases will assist in determining whether targeting health behaviours as a novel component of PTSD treatment aids in reducing CVD risk.

Biography:

Biswaroop Roy Chowdhury is an Indian Medical Nutritionist, a post graduate in Diabetes Education and American Heart Association Certified Advance Cardiovascular Life Support Instructor. He is the author of 25 books, including the national bestseller, “Diabetes Type I and II Cure in 72 Hours”. He is also the founder president of Indo-Vietnam Medical Board and runs his flagship program, “3-Days Diabetes Cure Residential Tour” in Vietnam and India, focused towards Type I and insulin-dependent Type II patients. Presently, he is involved in his ambitious project “Diabetes Free World” and is preparing to launch his 26th book “Diabetes Free World” in 71 languages, aiming to break the World Record of a book published in most languages. His book will be launched on World Diabetes Day (November 14, 2017) which is also exactly the 100th year since the discovery of first diabetes medicine.

Abstract:

Diabetes leads to a never-ending medicine and or insulin treatment for the diseased. Our goal was to establish and observe the effects of plant-based diet on the sugar levels of the diabetes patients. The major portion of plant-based diet consisted of raw fruits and vegetables. The clinical trial on 55 diabetes patients with a team of 6 medical associates was practiced for 3-days at Zorba, The Buddha, 10 – Tropical Drive, Ghitorni, New Delhi from 29th April to 1st May, 2016.

Medicines were eliminated from the first day of the trial. Both fasting and post-prandial readings were measured each day along with the weights of the participants. The subjects with varying diabetes history, age groups, type of diabetes, insulin dependency and demographic profiles were part of the trial.

Through the trial, 84% of patients reported controlled blood glucose levels and 16% of patients reported partially-controlled levels. Those with controlled levels could attain a healthy blood glucose range without medicines and/or insulin, along with the prescribed diet in 3-days. Those with partially controlled levels could attain a healthy blood glucose range with less than 50% of insulin than prescribed earlier.

Among diabetes type-2 patients the study reported 100% results with all the patients maintaining a healthy blood glucose level. While among diabetes type-1 patients, 43% reported healthy blood sugar levels through the diet and insulin reduction. The weight reduction for 55 patients in 3-days was reported as 1.14kgs of average weight loss per individual. The plant-based diet has been found effective to cure and control diabetes, eliminating or reducing the medicine or insulin requirements.

Biography:

Matej Stancik is a research fellow at the Internal Medicine Dept. I., Jessenius Faculty of Medicine, Comenius University in Bratislava, Slovak Republic. He received his Doctor´s degree from Comenius University in Bratislava in 2010. He obtained his Ph.D. degree from the Comenius University in Bratislava in 2014. His doctoral research was devoted to the adipokine regulation in stable coronary artery disease. His postdoctoral research is dedicated to adipokine regulation in the situation of both acute and chronic ischaemic heart disease. He is the author of various research grants, including the SRDA (Slovak Research and Development Agency) grant APVV-14-0153 and the author and co-author of various research articles.

Abstract:

The roles of vaspin in the pathogenesis of stable coronary artery disease (SCAD) have been repeatedly addressed in clinical studies. In our study, data of 106 SCAD patients who received coronary angiography (CA) and 85 healthy controls were analysed. The patients were divided into subgroups according to their pre-test probability (PTP) and the result of CA. Fasting vaspin was compared between subgroups of SCAD patients and between target group and controls. The effect of age and smoking on the result of coronary angiography was compared to the effect of vaspin using the binomial regression. We did not find significant difference in vaspin level between target group and controls. Unless the PTP was taken into account, we didn´t find vaspin difference in the target group, when dividing patients on the basis of presence of significant coronary stenosis. In the subgroup of patients with PTP 15% - 65 %, those with stenoses had higher vaspin (0,579 ± 0,898 ng/ml) than patients without significant stenoses (0,379 ± 0,732 ng/ml) t = -2,595; p = 0,012; d = 0,658; 1-β = 0,850. Age, smoking and vaspin contributed to the prediction of coronary stenosis in binomial regression model in low PTP (OR: 1.1, 4.9, and 8.7 respectively). According to our results, vaspin can´t be used as an independent marker for the presence of SCAD. Vaspin measurement might be clinically useful in patients with PTP below 66 %. This study was supported by the SRDA grant APVV – 14 – 0153 and by the VEGA grant 1/0160/16.

Biography:

Jiang He is a professor and Joseph Copes Chair of Epidemiology at the Tulane University School of Public Health and Tropical Medicine. He is also the Director of the Tulane University Translational Science Institute in New Orleans. He is an internationally well-known expert in the clinical, translational, and epidemiological research of cardio-metabolic diseases. He has conducted novel, NIH-funded studies in obesity, hypertension, diabetes, stroke, and cardiovascular disease. He has been the principal investigator and co-investigator for more than 30 major research awards from the NIH. Additionally he has authored more than 400 scientific articles which have been published in high-impact biomedical journals.

Abstract:

Most patients with diabetes have multiple uncontrolled metabolic risk factors. The overall objective of this cluster randomized trial is to test whether a collaborative care intervention will improve metabolic risk factors (glycated haemoglobin [HbA1C], systolic blood-pressure [SBP], and LDL-cholesterol) over 18 months (primary outcome in phase 1) and reduce major cardiovascular disease (CVD) over 3 years (primary outcome in phase 2) among patients with type-2 diabetes and increased CVD risk in China. The collaborative care intervention will be delivered by a team of primary care physicians, health managers, and nurses supported by diabetes specialists. The multicomponent interventions include health coaching for lifestyle modification and medication adherence and a decision support system using a stepped-care protocol for managing diabetes, hypertension, and dyslipidaemia based on clinical guidelines. The D4C trial will recruit 11,780 patients with diabetes and increased CVD risk from 38 community clinics in Xiamen, China. Nineteen clinics with approximately 310 patients each will be randomly assigned to intervention and 19 clinics to control. Study outcomes will be obtained at follow-up visits every 6 months. The D4C trial is designed to provide 90% statistical power to detect a 3.6% reduction in the combined changes in HbA1C, SBP, and LDL-cholesterol levels in phase 1 and a 20% reduction in major CVD in phase 2 at a significance level of 0.05 for a two-sided test. This trial will generate important data on an effective, practical and sustainable intervention program aimed at reducing the CVD burden among diabetes patients in populations with health disparities.

Biography:

Daniel Roberto Magdaleno Rodriguez is Mexican medical student of Superior School of Medicine (School of Medicine) at National Polytechnic Institute. He is a junior researcher who has been working at the obesity center of the School since 2013 on different research lines regargding obesity, diabetes, fatty liver, metabolic syndrome and hypertension. His most important recent research is focused on drug effectiveness and security for obesity and fatty livertreatment. He is also founder and CEO of AIMEDS A.C.

Abstract:

Obesity has become a public global health, we can not lose sight that this disease has reached epidemic global proportions, which is why the World Health Organization (WHO by the acronym in English) calls obesity as the epidemic of the century. The purpose of this study was to evaluate the efficacy and safety of anfepramona in patients with obesity against patients who recieve a placebo. It was a longitudinal, prospective and comparative study during 6 months. This study was conducted under 200 exogenous obese patients, aged between 18 and 60 years of both sexs with Body Mass Index (BMI by the acronym in English) between 30 and 45 kg/m2 Patients were randomized into two groups of 100 subjects each and were administered for six months with anfepramona (group 1) or placebo (group 2). All patients were under medical supervision during the six months of treatment and baseline blood determinations of glucose, total cholesterol, HDL and LDL, triglycerides and liver enzymes were made, these determinations were also made at the end of the study and compared with the initial figures, results were obtained Significant in different variables.